anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a sheep lambda 3 interferon mutant and a preparation method and application thereof. The invention firstly discloses a sheep lambda 3 interferon mutant, the amino acid sequence of which is shown in SEQ ID NO. 3. The 58 th amino acid of the sheep lambda 3 interferon mutant is mutated from alanine to valine to obtain the mutant with the amino acid sequence shown in SEQ ID NO.5, and the antiviral activity of the mutant is obviously improved. The invention further carries out amino acid single-site mutation, double-site mutation and multi-site mutation on the mutant with the amino acid sequence shown as SEQ ID NO.5 to obtain a plurality of sheep lambda 3 interferon mutants with improved antiviral activity. The antiviral activity of the sheep lambda 3 interferon mutant expressed in a silkworm bioreactor by using a silkworm baculovirus expression system is greatly improved. The sheep lambda 3 interferon mutant provided by the invention can be used for preparing a medicine or a reagent for preventing or treating sheep viral diseases.
Nucleotides of formula (I) (where R is a nucleoside residue and n is 2 or 3) (pref the corresponding phosphates of adenosine, cytidine, guanosine, inosine or uridine) are stabilised by binding or adsorbing them to an anion-exchanger (pref. a styrene copolymerisate contng. circled positive -N(CH3)3 groups), pref. by treating the anion-exchanger with a dilute aqs. soln. of the nucleotide, then washing the treated anion-exchanger with water until the wash water is neutral and carefully drying the washed product under reduced pressure. The product is sufficiently stable for use in preparations for oral administration which contain the nucleotide in admixture with other medicaments and/or carriers such as sucrose, lactose, glycine and mannitol.
Patients suffering from HF with central Sleep Apnea programmed to DDD/+15 bpm nocturnal rate (CRT + AOP) for 12 weeks. Intervention is the AOP in addition to CRT.
Doxorubicin (DOX) is a commonly used anthracycline in cancer chemotherapy. The clinical application of DOX is constrained by its cardiotoxicity. Myricetin (MYR) is a natural flavonoid widely present in many plants with antioxidant and anti-inflammatory properties. However, MYR's beneficial effects and mechanisms in alleviating DOX-induced cardiotoxicity (DIC) remain unknown. C57BL/6 mice were injected with 15 mg/kg of DOX to establish the DIC, and MYR solutions were administrated by gavage to investigate its cardioprotective potentials. Histopathological analysis, physiological indicators assessment, transcriptomics analysis, and RT-qPCR were used to elucidate the potential mechanism of MYR in DIC treatment. MYR reduced cardiac injury produced by DOX, decreased levels of cTnI, AST, LDH, and BNP, and improved myocardial injury and fibrosis. MYR effectively prevented DOX-induced oxidative stress, such as lowered MDA levels and elevated SOD, CAT, and GSH activities. MYR effectively suppressed NLRP3 and ASC gene expression levels to inhibit pyroptosis while regulating Caspase1 and Bax levels to reduce cardiac cell apoptosis. According to the transcriptomic analysis, glucose and fatty acid metabolism were associated with differential gene expression. KEGG pathway analysis revealed differential gene enrichment in PPAR and AMPK pathways, among others. Following validation, MYR was found to alleviate DIC by regulating glycolipid metabolism and AMPK pathway-related genes. Our findings demonstrated that MYR could mitigate DIC by regulating the processes of oxidative stress, apoptosis, and pyroptosis. MYR is critical in improving DOX-induced myocardial energy metabolism abnormalities mediated by the AMPK signaling pathway. In conclusion, MYR holds promise as a therapeutic strategy for DIC.
Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling. In addition, participants allocated to the neurodynamic group will also receive a nerve neurodynamic slider intervention targeting the main trunk of the sciatic nerve of the affected side during al treatment sessions (n=8).
BACKGROUND: Solid organ transplantation is a cost-effective treatment for end-stage organ failure. Organ donation after brain death is an important source of transplanted organs. Data are limited on the effects of brain injury or donor management on grafts. The consensus view has been that brain death creates a progressively proinflammatory environment. We aimed to investigate time-course changes across a range of cytokines in a donation after brain death cohort of donors who died of intracranial hemorrhage without any other systemic source of inflammation.
METHODS: A donor cohort was defined using the UK Quality in Organ Donation biobank. Serum levels of proteins involved in proinflammatory and brain injury pathways (tumor necrosis factor-alpha, interleukin-6, complement C5a, neuron-specific enolase, and glial fibrillary acidic protein) were measured from admission to organ recovery. Moving median analysis was used to combine donor trajectories and delineate a time-course.
RESULTS: A cohort of 27 donors with brain death duration between 10 and 30 h was created, with 24 donors contributing to the time-course analysis. We observed no increase in tumor necrosis factor-alpha or interleukin-6 throughout the donor management period. Neuronal injury marker and complement C5a remain high from admission to organ recovery, whereas glial fibrillary acidic protein rises around the confirmation of brain death.
CONCLUSIONS: We found no evidence of a progressive rise of proinflammatory mediators with prolonged duration of brain death, questioning the hypothesis of a progressively proinflammatory environment. Furthermore, the proposed approach allows us to study chronological changes and identify biomarkers or target pathways when logistical or ethical considerations limit sample availability.
FIELD: medicine, particularly, virology, immunology, gynecology, etc. SUBSTANCE: suppositories contain interferon inductor or interferon or their composition in ratio 2.1-3: 1. The proposed suppositories are applied for prophylaxis and treatment. They possess nonspecific antiviral action preventing replication of viruses and promoting their elimination. EFFECT: higher antiviral action. 10 cl, 3 tbl
This invention is concerned with packaged food products which contain specific combinations of functional additives aimed at addressing specific health indicators, in particular flatulence, gastro-intestinal health, stress and immune system responsiveness, in pet animals. There is provided a commercially packaged mammal pet food product that includes a manufactured, shelf-life stable food substrate and a combination of functional additives. The functional additives include at least one non-palatable plant-based remedy and/or dietary fibre source that are present to strengthen and/or maintain a specified health indicator of a mammal pet animal. The food product is portioned and packaged with the functional additives being present in predetermined concentrations and amounts sufficient to be effective in achieving said indications on regular feeding of the pet animal with said food product. The food substrate is present in a proportion sufficient to mask the flavour and/or odour of the non-palatable additive and is made-up of a unique combination of materials that are able to be processed at lower temperatures to preserve the natural botanical functional additive's activity. Functional additives intended to address dietary flatulence problems include a combination of Yucca extract, charcoal and salts of zinc, such as zinc acetate. Functional additives to promote or maintain gastro-intestinal health include a combination of L-glutamine, D-glucosamine sulphate, sugar beet pulp, slippery elm. Functional additives to strengthen or maintain a pet animal's natural body defenses include a combination of vitamin E, vitamin B complex, primrose oil, vitamin C and Marigold meal. Functional additives to promote or maintain reduction of stress and/or improved behavior of a pet animal include a combination of Valerian root extract, Kava root extract, vitamin B complex and magnesium salt.
In the palatal surgery group, the participants will receive palatal surgery.To evaluate the effect of treatments on the severity of OSA, tongue muscle strength and the space of the upper airway, the participants will receive polysomonogrphy test, tongue muscle strength test and computed tomography. The time of evaluation will include baseline, 3 and 6 months after treatment.
A method and kit for enhancing the natural fertility process. The kit includes a vaginal douche that is used prior to intercourse to enhance the sperm transportation and sustaining properties of the cervical mucous. The douche contains a balanced electrolyte solution, polysaccharides, and pH buffers. The kit also includes nutriceuticals specifically formulated for both the male and female which include amino acids, minerals, vitamins, herbs, phytoestrogens, and antioxidants along with a specified dosing regimen. A basal body temperature thermometer and chart is provided with instructions to confirm when and if ovulation will/did occur. Commercially available urinary chemical reagent strips are provided with instructions so as to predict/confirm if and when ovulation will occur. A lubricating medium will also be provided and utilized at the time of intercourse which is nonspermicidal and which contains polysaccharides which influence natural sperm motility. A detailed instruction book regarding the method and practice is provided along with dietary and lifestyle recommendations which have been shown to affect natural fertility.
Ankylosing spondylitis (AS) is an autoinflammatory disease that affects the sacroiliac joints, causing stiffness and pain in the back. MICA is a ligand of the NKG2D receptor, and an increase in its expression affects the immune response in various diseases. NLRP3 is a multiprotein complex that promotes the release of IL-1β, but its role in AS has been minimally explored. The objective of this study was to analyze the association and interaction of polymorphic variants of the MICA and NLRP3 genes in patients with AS. In this case-control study, patients with AS were included and compared with healthy controls of Mexican origin. The polymorphisms rs4349859 and rs116488202 of MICA and rs3806268 and rs10754558 of NLRP3 were genotyped using TaqMan probes. Associations were determined using logistic regression models, while interactions were analyzed by the multifactorial dimensionality reduction (MDR) method. A P value < 0.05 was considered statistically significant. The minor allele of rs4349859 (A) and rs116488202 (T) of MICA polymorphisms showed risk associations with AS (OR = 9.22, 95% CI = 4.26-20.0, P < 0.001; OR = 9.36, 95% CI = 4.17-21.0, P < 0.001), while the minor allele of the rs3806268 (A) polymorphism of NLRP3 was associated with protection (OR = 0.55, 95% CI = 0.33-0.91, P = 0.019). MDR analysis revealed synergistic interactions between the MICA and NLRP3 polymorphisms (P = 0.012). In addition, high- and low-risk genotypes were identified among these variants. The study findings suggest that the MICA rs4349859 A allele and rs116488202 T allele are associated with AS risk. An interaction between MICA and NLRP3 was observed which could increase the genetic risk in AS.
Development Group is used to establish the prediction model.2D and 3D ultrasonography are performed in this group. Through statistical analysis we obtain a new model.
PURPOSE:To produce the subject pyrazolotriazole derivative useful for therapy of hypertension, chronic heart failure, etc., according to various kinds of synthetic roots by reacting a pyrazolotriazole compound with a biphenylmethyl halide (or sulfonate) in steps. CONSTITUTION:A compound of formula I (R<1> and R<2> are independently H and a lower alkyl) is reacted with a compound of formula II (X<1> and X<2> are independently a halogen) and the resultant compound of formula III is converted through an oxidation reaction into an aldehyde. Further, the obtained compound is converted through an oxidative esterification reaction to an ester compound and the ester compound is converted to a carboxylic acid by hydrolysis of the ester part. The carboxylic acid part is converted to an alkoxycarbonyloxy group by using a carbonate derivative and X part of the resultant compound is modified by a compound of formula IV (R<6> and R<7> are independently a lower alkyl, etc.; R<8> is a lower alkyl; R<9> is H, Li, etc.). The substituent groups except the phenyl group on the tetrazole ring are subseauently eliminated, thus producing the objective pyrazolotriazole derivative of formula V (R<4> is a lower alkylene, etc.; R<5> is an alkyl, etc.) or its salt.
PROBLEM TO BE SOLVED: To chemically diminish oxidation reaction or free radical oxidation reaction and to reduce damage effect due to the reaction by topically or orally administering a specific compound. SOLUTION: Oxidation reaction or free radical oxidation reaction is chemically diminished by topically or orally administering a compound of formula I or II (R and R are each OH, CH3, CF3CH2O or CH3). A local combination drug such as gel, emulsion, cream, lotion, tonic, suspension or the like includes 0.05-20 wt.% compound of formula I or II. An oral combination drug for food, dietary therapy, alimentation and/or medicament includes 0.05-20 wt.% compound of formula I or II. The compound of formula I or II can be applied directly or in a semi-fabricated state (e.g. in an encapsulated state in liposomes or microcapsules).
Disorders of consciousness represent altered mental status at its most severe, comprising a continuum between coma, the vegetative state/unresponsive wakefulness syndrome, the minimally conscious state, and emergence from the minimally conscious state. Patients often transition between these levels throughout their recovery, and determining a patient's current level can be challenging, particularly in the acute care setting. Although healthcare providers have classically relied on a bedside neurological exam or the Glasgow Coma Scale to aid with assessment of consciousness, studies have identified multiple limitations of doing so. Neurobehavioral assessment measures, such as the Coma Recovery Scale-Revised, have been developed to address these shortcomings. Each behavioral metric has strengths as well as weaknesses when applied in the acute care setting. In this review, we appraise common assessment approaches, outline alternative measures for fine-tuning these assessments in the acute care setting, and highlight strategies for implementing these practices in an interdisciplinary manner.
BACKGROUND: Convulsive (CSE) and non-convulsive (NCSE) Status Epilepticus are a complication in 0.2-0.3% ischemic strokes. Large stroke and cortical involvement are the main risk factors for developing SE. This study evaluates the prevalence of SE in patients treated with endovascular thrombectomy (EVT) through EEG recording within 72- h from admission. Moreover, we compared clinical, radiological, and outcome measures in SE and no-SE patients.
MATERIALS AND METHODS: We collected retrospectively demographical and clinical characteristics of acute ischemic stroke patients who underwent EVT, admitted in the Stroke Unit (SU) of the University Hospital of Trieste between January 2018 and March 2020 who underwent EEG recording within 72- h from the symptoms' onset.
RESULTS: Out of 247 EVT patients, 138 met the inclusion criteria, of whom 9 (6.5%) showed SE with median onset time of 1 day (IQR 1-2). No difference was found between the two groups as for age, sex, risk factors, grade of recanalization, etiology of stroke, and closed vessel. The no-SE group presented higher NIHSS improvement rate (p=0.025) compared to the SE group. The sum of the lobes involved in the ischemic lesion was significantly higher in SE group (p=0.048).
CONCLUSION: SE after EVT in large strokes is a non-rare complication, with most being NCSE. Performing a rapid EEG assessment in a Stroke Unit setting may allow for a prompt recognition and treatment of SE in the acute/hyper-acute phase. SE may be correlated with worse clinical outcomes in patients with large vessel occlusion.
The use of blends of phosphoric acid and phytic acid (inositol (inositol hexakisphosphate) in phosphate based dental cements in phosphate based dental cements is new. The cements give higher bond strengths for fixing of crowns, and bridges. The liquor pref. contains 20-80% phosphoric acid and 1-20% phytic acid (I), the ratio of Phytic to phosphoric acids is between 1:80 and 1:3 pref . between 1:20 and 1:5. The liquor may contain 0.5-5% Al, pref. 2-3% Al.
PURPOSE: To obtain the subject permeable adhesive bandage not affected by liquid water by successively laminating a single layer of polymer support material, a medicine reservoir single layer containing a local administration medicine in a plasticized vinylic resin and a pressure-sensitive adhesive layer to each other. CONSTITUTION: This adhesive bandage comprises (A) a polymer support material single layer having two substantially flat surfaces comprising the first surface and the second surface (preferably comprising 60-95wt.% of a polyurethane and 5-40wt.% of PVC), (B) a medicine reservoir single layer consisting mainly of 20-70wt.% of polyvinyl chloride resin, 20-70wt.% of a high mol.wt. plasticizer (e.g. a high mol.wt. adipate ester plasticizer) and 0.25-15wt.% of a local administration medicine (e.g. tolnaftate, chlorhexidine) and adhered to the first flat surface of A, and (C9 a pressure-sensitive adhesive layer (preferably comprising an acrylate ester copolymer having hydrophilic groups such as hydroxyl groups, carbonyl groups, amino groups, etc.) adhering to the second flat surface of B, permitting the permeation of oxygen and steam and not affected by liquid water.
On day five of induction, D5-PBCR will be tested according to protocol. D5-PBCR (+) patients, will receive induction therapy consisting of venentoclax combined with IA regimen.
All participants will receive N-Acetylcysteine 1200 mg twice daily during four weeks of participation. Tolerability, marijuana use, and reactivity to marijuana cues will be investigated.
The invention discloses a traditional Chinese medicine externally-applied plaster for treating chronic bronchitis. The traditional Chinese medicine holds that an exterior reason is related to external-infection cold, and an internal reason is related to the malfunction of three organs of the lung, the spleen and the kidney. Cough and syndrome characterized by dyspnea are caused by deficiency of pulmonary and renal qi, unconsolidation of the kidney-qi, disordered sodium deriving and exhalation more than inhalation. Therefore, the traditional Chinese medicine externally-applied plaster for treating chronic bronchitis is prepared from the following traditional Chinese medicines of ophiopogon latifolius, aster ageratoides, ephedra, asarum, pinellia ternate, liquorice, semen brassicae, bulbus fritillariae cirrhosae, musk and rhizoma polygonati, and the traditional Chinese medicines have the efficacy on ventilating the lung, resolving phlegm, relieving cough and asthma, regulating qi and blood, invigorating spleen, supplementing qi and nourishing qi and Yin. The above medicines are grinded and screened by a sieve of 80 meshes, a proper quantity of plaster is blended by ginger juice, the plaster is pasted on a specific acupuncture point, and the effective rate is 94.8%. The traditional Chinese medicine externally-applied plaster for treating chronic bronchitis treats both principal and secondary aspects of disease for chronic bronchitis patients and is worth clinically popularizing and applying.
Brompheniramine maleate is a histamine antagonist, specifically an H1-receptor-blocking agent belonging to the alkylamine class of antihistamines. Antihistamines appear to compete with histamine for receptor sites on effector cells. Brompheniramine also has anticholinergic (drying) and sedative effects. Among the antihistaminic effects, it antagonizes the allergic response (vasodilation, increased vascular permeability, increased mucus secretion) of nasal tissue. Brompheniramine is well absorbed from the gastrointestinal tract, with peak plasma concentration after single, oral dose of 4 mg reached in 5 hours; urinary excretion is the major route of elimination, mostly as products of biodegradation; the liver is assumed to be the main site of metabolic transformation.

Pseudoephedrine acts on sympathetic nerve endings and also on smooth muscle, making it useful as a nasal decongestant. The nasal decongestant effect is mediated by the action of pseudoephedrine on a-sympathetic receptors, producing vasoconstriction of the dilated nasal arterioles. Following oral administration, effects are noted within 30 minutes with peak activity occurring at approximately one hour.

Dextromethorphan acts centrally to elevate the threshold for coughing. It has no analgesic or addictive properties. The onset of antitussive action occurs in 15 to 30 minutes after administration and is of long duration.
A wearable electronic user device comprising a processor, a touch-sensitive display and a timer is disclosed. The device can be used to register disease-related states of the user. The processor is configured to generate a scoring scale comprising at least three distinct scores concerning disease-related states of the user. The touch-sensitive display is configured to display the scoring scale as generated by the processor enabling a user interaction with the scoring scale. The timer is configured for generating timing information for registering timing instances associated with the detected user interaction. The processor is configured for detecting the user interaction with the touchsensitive display on or nearby the scoring scale to assign scoring information to the detected user interaction by associating the user interaction with one of the distinct scores. The processor is further configured to assign first scoring information to a first detected user interaction at a first position of the scoring scale associated with a first score at a first timing instance and to maintain this first scoring information during a time interval between the first timing instance and a second timing instance. The second timing instance coincides with a second user interaction at a second position of the scoring scale associated with a second distinct score. The processor is configured to assign a second scoring information to the second detected user interaction that is different from the first scoring information.